John LaMattina, Contributor

However, it would have been interesting had Novartis followed the plan initially outlined by Meanwell which would likely have benefited millions more patients. The high price of Leqvio won’t allow for that.

Even if the lower figure of $21,752 is used for argument purposes, the Covid-19 vaccines have saved the healthcare system $224.5 billion.

Going after processes that help generate drugs for children, however, is not the way to go.

But, shouldn’t the same scrutiny around pricing that has been given to the innovative drug companies also be applied to the healthcare systems giving the shots?

If there was a silver lining in the Covid-19 pandemic, it was the response of the biopharmaceutical industry in generating multiple new vaccines with unprecedented speed – vaccines that promise to bring a sense of normalcy to the world.

For the first time in more than 25 years, respect for the biopharmaceutical industry rose dramatically in 2020 due in large part due to the unprecedented delivery of vaccines against Covid-19.

Pfizer’s CFO, Frank D’Amelio, has raised eyebrows with recent comments about the future pricing of Pfizer’s Covid-19 vaccine.

If as the NYT reports, there truly are countries who would like access to this vaccine, why not offer the opportunity to acquire the AstraZeneca/Oxford vaccine to the World Health Organization, which has strongly advocated for more widespread access of…

In early July of 2020, Elisabeth Rosenthal published an op-ed in the New York Times warning about the biopharmaceutical industry trying to profit outrageously from a successful Covid-19 vaccine.

If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.